Fact checked byHeather Biele

Read more

January 22, 2024
1 min read
Save

M&S Technologies, Bruder launch BOSA device for OSD testing

Fact checked byHeather Biele
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • The device can capture and provide results for multiple dry eye tests in 15 seconds per eye, with additional test results in minutes.
  • The device also provides documentation for Demodex and blepharitis.

M&S Technologies and Bruder Healthcare have announced the launch of the M&S Bruder Ocular Surface Analyzer, an all-in-one device that captures and provides test results for dry eye disease in as little as 15 seconds per eye.

“With the system’s unmatched speed, accuracy and ease of use, doctors can manage dry eye patients more efficiently and effectively, improving outcomes through better data and boosting revenues through time savings,” Brent Jones, global head of vision care solutions at Hilco Vision, parent company of M&S Technologies and Bruder Healthcare, said in a company press release.

dry eye
BOSA can conduct multiple tests for dry eye disease in just 15 seconds, maximizing efficiency for clinicians. Image: Adobe Stock

According to the release, the M&S Bruder Ocular Surface Analyzer (BOSA) consolidates multiple tests for dry eye in one device, offering a comprehensive solution in a single practice location. The device’s noninvasive tests include auto interferometry to measure lipid layer thickness, auto tear meniscus height measurement, auto tear breakup time and auto blink evaluation, all of which generate results in 15 seconds per eye.

Other tests that provide results in minutes include auto meibography, bulbar redness, fluorescein staining, lissamine green staining, pupillometry test and white to white test. The device also provides documentation for Demodex and blepharitis, the release stated.

In addition, BOSA enables providers to create customizable treatment plans for patients and saves test results from each session.

“BOSA provides a ready-made hub to help identify, quantify and rectify OSD — with recommended treatments tailored to each patient’s test results,” Paul Karpecki, OD, FAAO, of the Kentucky Eye Institute, said in the release.